undamentalytics Newsletter
Sign in

Century Therapeutics, Inc. (IPSC) stock

Add to watchlist

Add holding +

NASDAQ: IPSC Nasdaq Biotechnology Next results ~November 12, 2026

Century Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Century Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 4 selling3 purchases and 20 sales by directors and officers, last 12 monthsInsider trades
  • Funds66 adding, 22 cuttingOf 21 active managers that changed their stake, 14 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Century Therapeutics files

Where Century Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $109m, up 1556.5% on a year earlier, slower than the 4121.1% growth a quarter earlier. Free-cash-flow margin rose to -95.9% from -4182.0% a year earlier. Operating margin widened to -15.8% from -2096.2%. The diluted share count is up 67.3% on a year earlier, which dilutes existing holders. It passes 2 of our 2 financial-health checks.

Our model value for Century Therapeutics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 12, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Century Therapeutics, Inc.'s trailing-twelve-month revenue grew 1556.5% year on year, with a free-cash-flow margin of -95.9%.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 1556.5% (-2564.6pp vs the prior quarter), the 3rd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 1556.5% over the last 12 months.
  • Margins widening. Operating margin is up 2080.3 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
  • Growth slowing. The growth rate is 2564.6 points lower than a quarter earlier.
  • Loss-making. Operating margin is -15.8%: costs exceed revenue.
  • Burning cash. Free cash flow was -95.9% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 67.3% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 101% and a beta of 2.1 against the S&P 500.

Latest results: FY2025 Q4

Filed March 12, 2026
Earnings per share
-$0.11 against an average estimate of -$0.12: beat by 2.5%
Share reaction
-6.3% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.11

Century Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.7%
  • 1 week+4.2%
  • 1 month-3.3%
  • This year+48.7%
  • 1 year+153.9%
  • 5 years-93.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$109M
Operating margin
-15.8%
Net margin
-8.8%
EPS (TTM, diluted)
$-0.77

Growth

Revenue growth
+1556.5%
Change in growth rate
−2564.6 pts
Share count change
+67.3%

Cash

Free cash flow (TTM)
-$88.1M
FCF margin
-95.9%
Stock pay % of revenue
6.3%

Earnings

Last results
August 12, 2026
Next results (est.)
November 12, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Leadership
  3. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Century Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025
Share price$5.13$3.32$1.01$0.99
Market value$166m$197m$79m$86m
+ Net debt (− = net cash)−$74m−$47m−$58m−$62m
Enterprise value$92m$150m$21m$24m
Multiples
Price / sales 32.0x88.1x12.1x0.8x
Price / earnings ————
Price / free cash flow ————
EV / EBITDA ————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.11 (range −$0.12 to −$0.08) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.47 −1310% — −100%
Next −$0.45 +4% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +1.4% on 90 days ago. In the last 30 days, 0 analysts raised Century Therapeutics, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Century Therapeutics, Inc., last 90 days
−$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.46 Current fiscal year, 60 days ago: −$0.46 Current fiscal year, 30 days ago: −$0.45 Current fiscal year, 7 days ago: −$0.45 Current fiscal year, Now: −$0.47 −$0.47 Next fiscal year, 90 days ago: −$0.46 Next fiscal year, 60 days ago: −$0.46 Next fiscal year, 30 days ago: −$0.45 Next fiscal year, 7 days ago: −$0.45 Next fiscal year, Now: −$0.45 −$0.45

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.46−$0.46
60 days ago −$0.46−$0.46
30 days ago −$0.45−$0.45
7 days ago −$0.45−$0.45
Now −$0.47−$0.45

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.12 −$0.11 +2.5%
Mar 2026 −$0.17 −$0.11 +37.1%
Dec 2025 −$0.30 −$0.25 +16.7%
Sept 2025 −$0.39 −$0.32 +16.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 12, 2026

No numeric guidance in Century Therapeutics, Inc.'s latest earnings release (filed August 12, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

5 analysts, Oct 2026
Buy480%
Hold120%
Sell00%

Monthly trend

  1. Oct 20261315
  2. Sep 20261315

Counts of recommendations published by analysts covering Century Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
16.2%
of tradable shares
Days to cover
37.58
at average volume
Short interest, 1 month
−1%
to October 15, 2026
Held by institutions
87%
of shares
Held by insiders
8.1%
of shares
Employees
78
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
IPSC−68%−35%−70%−2%+49%
Industry peers (median)−56%−17%−28%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
IPSC25%17%33%42%55%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
IPSC−70%−75%−81%−65%−57%
S&P 500−25%−10%−8%−19%−9%

Worst fall since June 18, 2021: 99% from August 13, 2021 to April 8, 2025. Getting back needed a 8108% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.47 – $2.94
From 52-week high
−49.7%
vs 50-day average
−14.2%
vs 200-day average
−29.2%
Volatility (1 year)
101%
Beta vs S&P 500
2.10

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±7.4%
After a week
5 up, 7 down
typical move ±6.6%
After a month
4 up, 8 down
typical move ±11.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 −6.3% +0.9% +2.4% −5.8%
May 13, 2026 +3.9% +1.4% −1.7% −1.7%
March 12, 2026 −14.3% −2.1% −8.8% −16.8%
November 13, 2025 −16.2% −1.7% −12.8% +1.6%
August 14, 2025 +5.4% −0.2% +1.5% −6.8%
May 15, 2025 +14.5% +1.1% +17.4% +19.2%
March 19, 2025 −6.5% +0.8% −5.4% −7.5%
January 13, 2025 −5.6% +0.3% −9.4% −24.4%
November 5, 2024 +10.3% +3.7% +11.9% +13.5%
August 8, 2024 −0.6% +2.8% −4.0% −11.0%
May 9, 2024 +2.0% +0.7% +2.0% +9.1%
March 14, 2024 +2.9% −0.9% −1.6% −24.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Century Therapeutics, Inc.
$0 $50M $100M $150M FY23 Q1 FY23 Q4 FY24 Q3 FY25 Q4 Revenue (TTM), FY23 Q1: $5.9M Revenue (TTM), FY23 Q2: $4.6M Revenue (TTM), FY23 Q3: $2.5M Revenue (TTM), FY23 Q4: $2.2M Revenue (TTM), FY24 Q1: $1.4M Revenue (TTM), FY24 Q2: $2M Revenue (TTM), FY24 Q3: $2.7M Revenue (TTM), FY24 Q4: $6.6M Revenue (TTM), FY25 Q1: $114.9M Revenue (TTM), FY25 Q2: $114.1M Revenue (TTM), FY25 Q3: $113.3M Revenue (TTM), FY25 Q4: $109.2M $109.2M

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY23 Q1 $5.9M
FY23 Q2 $4.6M
FY23 Q3 $2.5M
FY23 Q4 $2.2M
FY24 Q1 $1.4M
FY24 Q2 $2M
FY24 Q3 $2.7M
FY24 Q4 $6.6M
FY25 Q1 $114.9M
FY25 Q2 $114.1M
FY25 Q3 $113.3M
FY25 Q4 $109.2M
Revenue growth, TTM YoY Century Therapeutics, Inc.
-5000% 0% 5000% 10000% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 Revenue growth, TTM YoY, FY23 Q4: -57.0% Revenue growth, TTM YoY, FY24 Q1: -76.6% Revenue growth, TTM YoY, FY24 Q2: -55.3% Revenue growth, TTM YoY, FY24 Q3: 7.9% Revenue growth, TTM YoY, FY24 Q4: 194.9% Revenue growth, TTM YoY, FY25 Q1: 8286.8% Revenue growth, TTM YoY, FY25 Q2: 5489.0% Revenue growth, TTM YoY, FY25 Q3: 4121.1% Revenue growth, TTM YoY, FY25 Q4: 1556.5% 1556.5%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 -57.0%
FY24 Q1 -76.6%
FY24 Q2 -55.3%
FY24 Q3 7.9%
FY24 Q4 194.9%
FY25 Q1 8286.8%
FY25 Q2 5489.0%
FY25 Q3 4121.1%
FY25 Q4 1556.5%
Operating margin (TTM) Century Therapeutics, Inc.
-15000% -10000% -5000% 0% FY23 Q1 FY23 Q4 FY24 Q3 FY25 Q4 Operating margin (TTM), FY23 Q1: -2192.0% Operating margin (TTM), FY23 Q2: -2896.6% Operating margin (TTM), FY23 Q3: -5469.9% Operating margin (TTM), FY23 Q4: -6556.9% Operating margin (TTM), FY24 Q1: -10640.4% Operating margin (TTM), FY24 Q2: -7123.0% Operating margin (TTM), FY24 Q3: -5386.0% Operating margin (TTM), FY24 Q4: -2096.2% Operating margin (TTM), FY25 Q1: -28.4% Operating margin (TTM), FY25 Q2: -28.5% Operating margin (TTM), FY25 Q3: -29.9% Operating margin (TTM), FY25 Q4: -15.8% -15.8%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q1 -2192.0%
FY23 Q2 -2896.6%
FY23 Q3 -5469.9%
FY23 Q4 -6556.9%
FY24 Q1 -10640.4%
FY24 Q2 -7123.0%
FY24 Q3 -5386.0%
FY24 Q4 -2096.2%
FY25 Q1 -28.4%
FY25 Q2 -28.5%
FY25 Q3 -29.9%
FY25 Q4 -15.8%
FCF margin (TTM) Century Therapeutics, Inc.
-8000% -6000% -4000% -2000% 0% FY22 Q4 FY23 Q2 FY23 Q4 FY25 Q4 FCF margin (TTM), FY22 Q4: -318.4% FCF margin (TTM), FY23 Q1: -2276.9% FCF margin (TTM), FY23 Q2: -2655.2% FCF margin (TTM), FY23 Q3: -4182.0% FCF margin (TTM), FY23 Q4: -4567.5% FCF margin (TTM), FY24 Q1: -7201.5% FCF margin (TTM), FY24 Q2: -5020.0% FCF margin (TTM), FY25 Q4: -95.9% -95.9%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period FCF margin (TTM)
FY22 Q4 -318.4%
FY23 Q1 -2276.9%
FY23 Q2 -2655.2%
FY23 Q3 -4182.0%
FY23 Q4 -4567.5%
FY24 Q1 -7201.5%
FY24 Q2 -5020.0%
FY25 Q4 -95.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 5 2 7 109
EBITDA −125 −134 −125 −4
Operating income −134 −147 −138 −17
Net income −131 −137 −127 −10
Diluted EPS −$2.96 −$2.30 −$1.61 −$0.14
Growth (year on year)
Revenue — −57.0% +194.8% +>999%
Margins
EBITDA margin <−999% <−999% <−999% −3.8%
Operating margin <−999% <−999% <−999% −15.8%
Net margin <−999% <−999% <−999% −8.8%
Free-cash-flow margin −318.4% <−999% <−999% −95.9%
Cash flow
Cash from operations 14 −88 −110 −104
Capital spending 31 14 0 1
Free cash flow −17 −102 −110 −105
Stock-based pay 11 15 13 7
Free cash flow after stock pay −27 −117 −123 −112
Balance sheet
Cash 84 47 58 62
Total debt 10 — 0 0
Net debt (negative = net cash) −74 −47 −58 −62
Diluted shares 32m 59m 79m 87m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $287m
Short-term assets $125mLonger-term assets $162m
What it owes, and who funded it · $287m
Short-term liabilities $15mLonger-term liabilities $40mShareholders' equity $232m
  • Short-term assets cover short-term liabilities $125m of assets due within a year against $15m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $125m short-term assets against $40m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Century Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+67.3%
year over year
R&D spending
67.0%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated IPSC XNCR KYMR SPRY RCUS MESO Median
Revenue, last 12 months $109m $105m $102m $117m $117m $120m $58m
Revenue growth, last 12 months >999% −28.6% 133.8% 4.1% −55.3% 599.2% 12.7%
Revenue growth, 3-year average 175.9% −2.5% 29.7% 711.3% −1.1% — 14.3%
Revenue growth, latest quarter −100.0% 17.5% −100.0% 114.2% −74.4% — 10.2%
Gross margin — — 0.0% — — 86.1% 82.9%
Operating margin −15.8% −205.8% −396.0% −185.0% −415.4% — −187.2%
Operating margin, 3-year average <−999% −136.0% −461.5% <−999% −221.0% — −365.3%
Net margin −8.8% −155.6% −341.8% −184.2% −393.2% −47.8% −163.5%
Cash from operations / revenue −95.2% −196.1% −281.3% −168.0% −405.1% −36.4% −162.3%
Free-cash-flow margin −95.9% −198.4% −282.6% −168.1% −406.0% −37.1% −156.7%
Free-cash-flow margin, 3-year average — −128.0% −326.1% <−999% −214.9% — −310.0%
Stock pay / revenue 6.3% 37.2% 66.7% 26.7% 53.8% 12.4% 19.2%
Change in share count 67.3% 5.2% 17.6% −3.9% 22.7% 7.2% 8.3%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$387M
Institutions reporting
99
Shares held vs prior quarter
▲ 13.9%
Positions opened / closed
37 / 10

Top buyers and sellers, Q2 2026: 66 institutions bought and 22 sold ; the biggest buyer was Blackrock, Inc (+6.6M shares) and the biggest seller Syncona Portfolio Ltd (−1.2M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $43.5M 17.8M 11.2% 0.0%
Tcg Crossover Management, LLC $43.4M 17.8M 11.2% 0.0%
Versant Venture Management, LLC $29.8M 12.2M 7.7% 0.0%
Deep Track Capital, LP $23.2M 9.5M 6.0% ▼ 0.3%
Venrock Adviser, LLC $21.3M 8.7M 5.5% 0.0%
Commodore Capital LP $21.3M 8.7M 5.5% 0.0%
RTW Investments, LP $21.3M 8.7M 5.5% 0.0%
Blackrock, Inc. $19.8M 8.1M 5.1% ▲ 430.8%
Vanguard Capital Management LLC $14M 5.7M 3.6% ▲ 0.3%
Balyasny Asset Management L.P. $13.5M 5.5M 3.5% ▲ 10.1%
Point72 Asset Management, L.P. $12.2M 5.0M 3.2% ▼ 16.5%
Seven Fleet Capital Management LP $10.7M 4.3M 2.8% ▲ 47.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Century Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $97,011 3 trades by 2 insiders, last 12 months Insider sales History → $86,061 20 trades by 4 insiders · 0% under pre-set plans
Net ▲ $10,950 net buying
Insider Date Trade Shares Price Value
Carr Douglas SVP Finance & Operations September 14, 2026 Sell 1,658 $1.93 $3,200
Russotti Gregory See Remarks September 14, 2026 Sell 2,587 $1.93 $4,993
Carr Douglas SVP Finance & Operations September 8, 2026 Sell 254 $2.05 $521
Russotti Gregory See Remarks September 8, 2026 Sell 534 $2.05 $1,095
Carr Douglas SVP Finance & Operations August 3, 2026 Sell 275 $1.98 $544
Carr Douglas SVP Finance & Operations June 12, 2026 Sell 1,654 $2.23 $3,688
Russotti Gregory See Remarks June 12, 2026 Sell 2,584 $2.23 $5,762
Carr Douglas SVP Finance & Operations June 8, 2026 Sell 249 $2.11 $525
Russotti Gregory See Remarks June 8, 2026 Sell 524 $2.11 $1,106
Carr Douglas SVP Finance & Operations May 4, 2026 Sell 264 $2.34 $618
Russotti Gregory See Remarks March 12, 2026 Sell 10,076 $2.55 $25,694
Carr Douglas SVP Finance & Operations March 12, 2026 Sell 7,043 $2.55 $17,960

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced

  • August 12, 2026
  • May 13, 2026
  • March 12, 2026
  • November 13, 2025
  • August 14, 2025
  • May 15, 2025

Recent SEC filings

Data status

When each part of this page on Century Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Century Therapeutics, Inc. in brief

What does Century Therapeutics, Inc. do?
Century Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Century Therapeutics, Inc.'s stock ticker?
Century Therapeutics, Inc. trades under the ticker IPSC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Century Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Century Therapeutics, Inc. reported revenue of $109M, 1556.5% higher than a year earlier, according to its SEC filings.
What is Century Therapeutics, Inc.'s free cash flow?
Century Therapeutics, Inc.'s free-cash-flow margin is -95.9% of revenue over the trailing twelve months.
Who are Century Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Tcg Crossover Management, LLC and Versant Venture Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Century Therapeutics, Inc.'s market cap?
On December 31, 2025, Century Therapeutics, Inc.'s market capitalisation was about $86.1M and net debt of -$61.9M. Market figures come from third-party market data and may be delayed.
Who are Century Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Century Therapeutics, Inc. are Xencor Inc, Kymera Therapeutics, Inc., ARS Pharmaceuticals, Inc., Arcus Biosciences, Inc. and Mesoblast LTD. The side-by-side comparison below sets their revenue, margins and growth against Century Therapeutics, Inc.'s.
Are insiders buying or selling Century Therapeutics, Inc. stock?
Over the last 12 months, Century Therapeutics, Inc.'s directors and officers reported 3 open-market purchases and 20 sales on Form 4. The insider trading page charts every trade.
When is Century Therapeutics, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Century Therapeutics, Inc. announces its own schedule.